UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-A

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR 12(g) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

 

Matinas BioPharma Holdings, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

     
Delaware   46-3011414
(State of incorporation or organization)   (I.R.S. Employer Identification No.)

     

1545 Route 206 South, Suite 302

Bedminster, NJ

   07921
(Address of principal executive offices)   (Zip Code)

 

Title of each class Name of each exchange on
To be so registered which each class is to be registered
   
Common Stock, $0.0001 par value per share NYSE MKT LLC

 

Securities to be registered pursuant to Section 12(b) of the Act: Common Stock, $0.0001 per share

 

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), please check the following box ☒

 

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), please check the following box ☐


Securities Act registration statement file number to which this form relates:

 

Securities to be registered pursuant to Section 12(g) of the Act:

 

 
 

 

Item 1. Description of Registrant’s Securities to be Registered.

 

Matinas BioPharma Holdings, Inc. (the “Company”) hereby incorporates by reference the description of its securities to be registered hereunder contained in the Prospectus dated November 18, 2016 under “Description of Capital Stock”, filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 22, 2016 under Rule 424(b)(3), pursuant to the Company’s registration statement on Form S-1 (File No. 333-214391), filed with the SEC on November 2, 2016, under the Securities Act of 1933, as amended.

 

 

    

 

 

Item 2. Exhibits.

 

Under the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed herewith or incorporated by reference herein because no other securities of the Company are registered on the NYSE MKT LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

 

 

 - 3 - 

 

 

SIGNATURE

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

             
        Matinas BioPharma Holdings, Inc.  
         
Date: March 1, 2017       By: /s/ Roelof Rongen  
        Name: Roelof Rongen  
        Title:

Chief Executive Officer